Results 31 to 40 of about 1,793 (169)

Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study

Acta Dermato-Venereologica, 2018
Treatment of alopecia totalis and alopecia universalis is often challenging and unsatisfactory. Recently, Janus kinase inhibitor has shown promising results.
Jung-Won Shin, Chang-Hun Huh, Min-Woo Kim, Ji-Su Lee, Ohsang Kwon, Soyun Cho, Hyun-sun Park   +6 more
doaj   +1 more source

Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib

Frontiers in Medicine, 2023
Alopecia areata (AA) is a non-scarring hair loss disorder. Alopecia totalis (AT) and alopecia universalis (AU) are the severe subtypes of AA. Age of onset before 6 years of age, disease duration of more than 1 year, and extensive alopecia involving more ...
Lu Cai, Lu Cai, Yi Wei, Min Zhao, Jia Zhuo, Xiao Tao, Mao Lin, Mao Lin   +7 more
doaj   +1 more source

Use of intramuscular triamcinolone acetonide in intermediate responders to janus kinase inhibition for alopecia areata: Case report

Journal of Dermatology and Dermatologic Surgery, 2021
Janus kinase (JAK) inhibitors have been identified as an effective treatment option for severe alopecia areata (AA), but response is variable among patients.
Erinolaoluwa F Araoye, Crystal Aguh
doaj   +1 more source

Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study

Vaccines, 2022
Limited data concerning the development of autoimmune skin diseases after COVID-19 vaccination are currently available. Recently, a few reports described the development, worsening or recurrence of alopecia areata after the administration of COVID-19 ...
Francesco Tassone, Simone Cappilli, Flaminia Antonelli, Ruggiero Zingarelli, Andrea Chiricozzi, Ketty Peris   +5 more
doaj   +1 more source

Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma

JEADV Clinical Practice, EarlyView.
ABSTRACT Alopecia areata (AA) is an autoimmune disease characterized by non‐scarring hair loss of the scalp and/or body, with an unpredictable and variable clinical course. Its etiology is not entirely understood, although evidence suggests that environmental, immunological, and genetic factors contribute to disease development.
Marco Rubatto, Eleonora Bongiovanni, Veronica Arese, Michela Camilla Milanesio, Alessia Reali, Massimo Chiarpenello, Gianmauro Numico, Marcella Occelli   +7 more
wiley   +1 more source

Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark

Acta Dermato-Venereologica
The emergence of new systemic treatments for alopecia areata underscores the importance of estimating rates of potential treatment safety events among individuals with alopecia areata.
Sissel Brandt Toft Sørensen, Prethibha George, Oladayo Jagun, Robert Wolk, Lynne Napatalung, Samuel H. Zwillich, Lars Iversen, Vera Ehrenstein   +7 more
doaj   +1 more source

Scale of Alopecia Areata Distress (SAAD‐41): Initial Validation Part 2—Scoring, Preliminary Reference Values and Validity

JEADV Clinical Practice, EarlyView.
The SAAD‐41 is a 41‐item scale developed to comprehensively assess Alopecia Areata psychosocial patient‐reported outcomes. Results support scoring the scale at the subdomain level and provisionally at the total‐score level. The total‐score can be calculated as a sum of the 41 SAAD items, with the sum referred to as the SAAD‐41‐Total.
Kristina Gorbatenko‐Roth, Mattea Trinitapoli, Sarah Wood, Irmina Wallander, Jaime Nugent, Maria Hordinsky   +5 more
wiley   +1 more source

Efficacy of oral tofacitinib in moderate to severe alopecia areata, totalis and universalis at the tertiary care hospital, Karachi

Journal of the Pakistan Medical Association
Objective: To evaluate the effectiveness and safety of oral tofacitinib in treating patients with different forms of alopecia. Method: The prospective, interventional, open-label study was conducted at the Department of Dermatology, Jinnah ...
Misbah Zari Qadir, Rabia Ghafoor, Muhammad Khurram Salahuddin, Parisa Sanawar, Nazia Jabeen, Khadija Asadullah   +5 more
doaj   +1 more source

Adult onset loose anagen hair syndrome with alopecia totalis [PDF]

Al Ameen Journal of Medical Sciences, 2008
A young adult male patient presented with diffuse hair loss of two years duration. Clinical features and investigations were suggestive of loose anagen hair syndrome. He developed alopecia totalis during follow-up.
Aparna Palit
doaj  

Early On‐Treatment Change in SALT as a Pragmatic Predictor of Ritlecitinib Response in Moderate‐To‐Severe Alopecia Areata: A Real‐World Cohort Study

International Journal of Dermatology, EarlyView.
Ritlecitinib induced rapid clinical improvement in moderate‐to‐severe alopecia areata in real‐world practice. Early change in SALT at Week 12 strongly discriminated Week‐24 responders, supporting a pragmatic treat‐to‐target checkpoint, alongside improvements in clinician‐reported and patient‐reported outcomes and a favorable safety profile.
Giuseppe Gallo, Isotta Giunipero di Corteranzo, Pietro Quaglino, Simone Ribero, Francois Rosset   +4 more
wiley   +1 more source